Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.

Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL.

J Psychopharmacol. 2020 Feb;34(2):167-180. doi: 10.1177/0269881119895520. Epub 2020 Jan 16.

PMID:
31941394
2.

From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner.

Kettner H, Gandy S, Haijen ECHM, Carhart-Harris RL.

Int J Environ Res Public Health. 2019 Dec 16;16(24). pii: E5147. doi: 10.3390/ijerph16245147.

3.

Decreased directed functional connectivity in the psychedelic state.

Barnett L, Muthukumaraswamy SD, Carhart-Harris RL, Seth AK.

Neuroimage. 2019 Dec 17;209:116462. doi: 10.1016/j.neuroimage.2019.116462. [Epub ahead of print]

4.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.

Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S.

Psychopharmacology (Berl). 2019 Dec 18. doi: 10.1007/s00213-019-05417-7. [Epub ahead of print]

PMID:
31853557
5.

Neural correlates of the DMT experience assessed with multivariate EEG.

Timmermann C, Roseman L, Schartner M, Milliere R, Williams LTJ, Erritzoe D, Muthukumaraswamy S, Ashton M, Bendrioua A, Kaur O, Turton S, Nour MM, Day CM, Leech R, Nutt DJ, Carhart-Harris RL.

Sci Rep. 2019 Nov 19;9(1):16324. doi: 10.1038/s41598-019-51974-4.

6.

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Carhart-Harris RL, Friston KJ.

Pharmacol Rev. 2019 Jul;71(3):316-344. doi: 10.1124/pr.118.017160. Review.

7.

Replication and extension of a model predicting response to psilocybin.

Russ SL, Carhart-Harris RL, Maruyama G, Elliott MS.

Psychopharmacology (Berl). 2019 Nov;236(11):3221-3230. doi: 10.1007/s00213-019-05279-z. Epub 2019 Jun 15.

PMID:
31203401
8.

Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin.

Lord LD, Expert P, Atasoy S, Roseman L, Rapuano K, Lambiotte R, Nutt DJ, Deco G, Carhart-Harris RL, Kringelbach ML, Cabral J.

Neuroimage. 2019 Oct 1;199:127-142. doi: 10.1016/j.neuroimage.2019.05.060. Epub 2019 May 25.

PMID:
31132450
9.

Psychedelics as a treatment for disorders of consciousness.

Scott G, Carhart-Harris RL.

Neurosci Conscious. 2019 Apr 21;2019(1):niz003. doi: 10.1093/nc/niz003. eCollection 2019.

10.

Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition.

Atasoy S, Vohryzek J, Deco G, Carhart-Harris RL, Kringelbach ML.

Prog Brain Res. 2018;242:97-120. doi: 10.1016/bs.pbr.2018.08.009. Epub 2018 Oct 25. Review.

PMID:
30471684
11.

Predicting Responses to Psychedelics: A Prospective Study.

Haijen ECHM, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, Nutt D, Daws RE, Hampshire ADG, Lorenz R, Carhart-Harris RL.

Front Pharmacol. 2018 Nov 2;9:897. doi: 10.3389/fphar.2018.00897. eCollection 2018.

12.

How do psychedelics work?

Carhart-Harris RL.

Curr Opin Psychiatry. 2019 Jan;32(1):16-21. doi: 10.1097/YCO.0000000000000467. Review.

PMID:
30394903
13.

More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression.

Lyons T, Carhart-Harris RL.

Front Psychol. 2018 Oct 12;9:1721. doi: 10.3389/fpsyg.2018.01721. eCollection 2018.

14.

Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD.

Deco G, Cruzat J, Cabral J, Knudsen GM, Carhart-Harris RL, Whybrow PC, Logothetis NK, Kringelbach ML.

Curr Biol. 2018 Oct 8;28(19):3065-3074.e6. doi: 10.1016/j.cub.2018.07.083. Epub 2018 Sep 27.

15.

Psychedelics, Meditation, and Self-Consciousness.

Millière R, Carhart-Harris RL, Roseman L, Trautwein FM, Berkovich-Ohana A.

Front Psychol. 2018 Sep 4;9:1475. doi: 10.3389/fpsyg.2018.01475. eCollection 2018.

16.

Serotonin, psychedelics and psychiatry.

Carhart-Harris RL.

World Psychiatry. 2018 Oct;17(3):358-359. doi: 10.1002/wps.20555. No abstract available.

17.

Effects of psilocybin therapy on personality structure.

Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart-Harris RL.

Acta Psychiatr Scand. 2018 Nov;138(5):368-378. doi: 10.1111/acps.12904. Epub 2018 Jun 19.

18.

Psilocybin and MDMA reduce costly punishment in the Ultimatum Game.

Gabay AS, Carhart-Harris RL, Mazibuko N, Kempton MJ, Morrison PD, Nutt DJ, Mehta MA.

Sci Rep. 2018 May 29;8(1):8236. doi: 10.1038/s41598-018-26656-2.

19.

The entropic brain - revisited.

Carhart-Harris RL.

Neuropharmacology. 2018 Nov;142:167-178. doi: 10.1016/j.neuropharm.2018.03.010. Epub 2018 Mar 14. Review.

PMID:
29548884
20.

Psychedelics and the essential importance of context.

Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, Kaelen M.

J Psychopharmacol. 2018 Jul;32(7):725-731. doi: 10.1177/0269881118754710. Epub 2018 Feb 15.

PMID:
29446697
21.

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.

Carrillo F, Sigman M, Fernández Slezak D, Ashton P, Fitzgerald L, Stroud J, Nutt DJ, Carhart-Harris RL.

J Affect Disord. 2018 Apr 1;230:84-86. doi: 10.1016/j.jad.2018.01.006.

PMID:
29407543
22.

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

Roseman L, Nutt DJ, Carhart-Harris RL.

Front Pharmacol. 2018 Jan 17;8:974. doi: 10.3389/fphar.2017.00974. eCollection 2017.

23.

Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.

Lyons T, Carhart-Harris RL.

J Psychopharmacol. 2018 Jul;32(7):811-819. doi: 10.1177/0269881117748902. Epub 2018 Jan 17.

24.

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.

Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL.

Neuropharmacology. 2018 Nov;142:263-269. doi: 10.1016/j.neuropharm.2017.12.041. Epub 2017 Dec 27.

25.

Connectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organization under LSD.

Atasoy S, Roseman L, Kaelen M, Kringelbach ML, Deco G, Carhart-Harris RL.

Sci Rep. 2017 Dec 15;7(1):17661. doi: 10.1038/s41598-017-17546-0.

26.

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ.

Psychopharmacology (Berl). 2018 Feb;235(2):399-408. doi: 10.1007/s00213-017-4771-x. Epub 2017 Nov 8.

27.

LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm.

Timmermann C, Spriggs MJ, Kaelen M, Leech R, Nutt DJ, Moran RJ, Carhart-Harris RL, Muthukumaraswamy SD.

Neuropharmacology. 2018 Nov;142:251-262. doi: 10.1016/j.neuropharm.2017.10.039. Epub 2017 Nov 20.

PMID:
29101022
28.

Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.

Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, Curran HV, Carhart-Harris RL.

Psychopharmacology (Berl). 2018 Feb;235(2):459-466. doi: 10.1007/s00213-017-4754-y. Epub 2017 Oct 30.

29.

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.

Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ.

Sci Rep. 2017 Oct 13;7(1):13187. doi: 10.1038/s41598-017-13282-7.

30.

Serotonin and brain function: a tale of two receptors.

Carhart-Harris RL, Nutt DJ.

J Psychopharmacol. 2017 Sep;31(9):1091-1120. doi: 10.1177/0269881117725915. Epub 2017 Aug 31. Review.

31.

Psychedelics and connectedness.

Carhart-Harris RL, Erritzoe D, Haijen E, Kaelen M, Watts R.

Psychopharmacology (Berl). 2018 Feb;235(2):547-550. doi: 10.1007/s00213-017-4701-y. Epub 2017 Aug 10.

PMID:
28795211
32.

Psychedelics, Personality and Political Perspectives.

Nour MM, Evans L, Carhart-Harris RL.

J Psychoactive Drugs. 2017 Jul-Aug;49(3):182-191. doi: 10.1080/02791072.2017.1312643. Epub 2017 Apr 26.

PMID:
28443703
33.

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Carhart-Harris RL, Goodwin GM.

Neuropsychopharmacology. 2017 Oct;42(11):2105-2113. doi: 10.1038/npp.2017.84. Epub 2017 Apr 26. Review.

34.

Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.

Schartner MM, Carhart-Harris RL, Barrett AB, Seth AK, Muthukumaraswamy SD.

Sci Rep. 2017 Apr 19;7:46421. doi: 10.1038/srep46421.

35.

Psychedelics and the science of self-experience.

Nour MM, Carhart-Harris RL.

Br J Psychiatry. 2017 Mar;210(3):177-179. doi: 10.1192/bjp.bp.116.194738.

PMID:
28249943
36.

Altered Insula Connectivity under MDMA.

Walpola IC, Nest T, Roseman L, Erritzoe D, Feilding A, Nutt DJ, Carhart-Harris RL.

Neuropsychopharmacology. 2017 Oct;42(11):2152-2162. doi: 10.1038/npp.2017.35. Epub 2017 Feb 14.

37.

Question-based Drug Development for psilocybin - Authors' reply.

Carhart-Harris RL, Nutt DJ.

Lancet Psychiatry. 2016 Sep;3(9):807. doi: 10.1016/S2215-0366(16)30217-6. No abstract available.

PMID:
27568266
38.

Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI).

Nour MM, Evans L, Nutt D, Carhart-Harris RL.

Front Hum Neurosci. 2016 Jun 14;10:269. doi: 10.3389/fnhum.2016.00269. eCollection 2016.

39.

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ.

Lancet Psychiatry. 2016 Jul;3(7):619-27. doi: 10.1016/S2215-0366(16)30065-7. Epub 2016 May 17.

40.

LSD-induced entropic brain activity predicts subsequent personality change.

Lebedev AV, Kaelen M, Lövdén M, Nilsson J, Feilding A, Nutt DJ, Carhart-Harris RL.

Hum Brain Mapp. 2016 Sep;37(9):3203-13. doi: 10.1002/hbm.23234. Epub 2016 May 6.

41.

LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion.

Roseman L, Sereno MI, Leech R, Kaelen M, Orban C, McGonigle J, Feilding A, Nutt DJ, Carhart-Harris RL.

Hum Brain Mapp. 2016 Aug;37(8):3031-40. doi: 10.1002/hbm.23224. Epub 2016 Apr 29.

42.

Neural correlates of the LSD experience revealed by multimodal neuroimaging.

Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ.

Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4853-8. doi: 10.1073/pnas.1518377113. Epub 2016 Apr 11.

43.

Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide.

Speth J, Speth C, Kaelen M, Schloerscheidt AM, Feilding A, Nutt DJ, Carhart-Harris RL.

J Psychopharmacol. 2016 Apr;30(4):344-53. doi: 10.1177/0269881116628430.

44.

The paradoxical psychological effects of lysergic acid diethylamide (LSD).

Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, Feilding A, Nutt DJ.

Psychol Med. 2016 May;46(7):1379-90. doi: 10.1017/S0033291715002901. Epub 2016 Feb 5.

45.

LSD enhances the emotional response to music.

Kaelen M, Barrett FS, Roseman L, Lorenz R, Family N, Bolstridge M, Curran HV, Feilding A, Nutt DJ, Carhart-Harris RL.

Psychopharmacology (Berl). 2015 Oct;232(19):3607-14. doi: 10.1007/s00213-015-4014-y. Epub 2015 Aug 11.

46.

Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.

Lebedev AV, Lövdén M, Rosenthal G, Feilding A, Nutt DJ, Carhart-Harris RL.

Hum Brain Mapp. 2015 Aug;36(8):3137-53. doi: 10.1002/hbm.22833. Epub 2015 May 22.

PMID:
26010878
47.

Drug models of schizophrenia.

Steeds H, Carhart-Harris RL, Stone JM.

Ther Adv Psychopharmacol. 2015 Feb;5(1):43-58. doi: 10.1177/2045125314557797. Review.

48.
49.

LSD enhances suggestibility in healthy volunteers.

Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ.

Psychopharmacology (Berl). 2015 Feb;232(4):785-94. doi: 10.1007/s00213-014-3714-z. Epub 2014 Sep 23.

PMID:
25242255
50.

The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers.

Roseman L, Leech R, Feilding A, Nutt DJ, Carhart-Harris RL.

Front Hum Neurosci. 2014 May 27;8:204. doi: 10.3389/fnhum.2014.00204. eCollection 2014.

Supplemental Content

Loading ...
Support Center